| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6010100 | Epilepsy & Behavior | 2016 | 8 Pages |
Abstract
The results of PREVAIL OLE are consistent with those from PREVAIL and demonstrate that adjunctive treatment with up to 400Â mg/day of USL255 may be a safe and effective treatment option for a variety of adult patients with refractory POS.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Steve S. Chung, R. Edward Hogan, Ilan Blatt, Balduin Lawson P., Huy Nguyen, Annie M. Clark, Bob Anders, Mark B. Halvorsen, on behalf of the PREVAIL OLE Study Group on behalf of the PREVAIL OLE Study Group,